The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | The role of ruxolitinib in the treatment of early-stage myelofibrosis
Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the management of early-stage myelofibrosis (MF). He clarifies that early MF should not be confused with pre-fibrotic MF, a distinct disease entity. Early MF is still overt but presents with a less severe phenotype. Dr Bose highlights the role of ruxolitinib, which should be administered early to improve outcomes, as demonstrated by the COMFORT studies (NCT00952289, NCT00934544). This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
